Zykov V P, Serebrennikova E B, Panchenko T N, Sycheva Ya B, Presnyakova S N, Mazur E L, Salova M N, Golubeva E S, Khromova S K
Russian Medical Academy for Continuing Professional Education, Moscow, Russia.
Pichugin City Clinical Hospital for Children, Perm, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):27-31. doi: 10.17116/jnevro20181183127-31.
To study the efficacy and tolerability of cortexin in the treatment of cognitive dysfunction in children.
The study included 635 patients, aged 3-7 years. Patients were divided into 4 clinical groups: group 1 (269 children with attention deficit hyperactivity disorder (ADHD)), group 2 (215 children with speech delay), group 3 (82 patients with the consequences of a perinatal lesion of the central nervous system), group 4 (69 patients with asthenic/neurotic syndrome). Attention, visual memory and thinking were assessed before and after treatment. Standard treatment of cortexin, including 10 intramuscular injections, was used.
The reliable effect of cortexin on cognitive impairment was shown. The best response to treatment was observed in patients with ADHD, aged 3-4 years, in particular on the tests measuring thinking. The tolerability of cortexin was good. It has been concluded that cortexin is an effective drug for treatment of children with ADHD, speech delay and consequences of a perinatal lesion of the central nervous system.
研究脑活素治疗儿童认知功能障碍的疗效和耐受性。
该研究纳入了635名3至7岁的患者。患者被分为4个临床组：第1组（269名患有注意力缺陷多动障碍（ADHD）的儿童），第2组（215名语言发育迟缓的儿童），第3组（82名患有中枢神经系统围产期损伤后遗症的患者），第4组（69名患有虚弱/神经症综合征的患者）。在治疗前后评估注意力、视觉记忆和思维能力。采用脑活素的标准治疗方法，包括10次肌肉注射。
显示了脑活素对认知障碍的可靠疗效。在3至4岁的ADHD患者中观察到对治疗的最佳反应，尤其是在测量思维能力的测试中。脑活素的耐受性良好。得出的结论是，脑活素是治疗患有ADHD、语言发育迟缓以及中枢神经系统围产期损伤后遗症儿童的有效药物。
